在接受肺移植的肺动脉高血压患者中使用Sotatercept
Justin P Rosenheck1, Kashika Goyal1, Tara Fallah2
1Ohio State University, Department of Internal Medicine, Division of Pulmonary Critical Care and Sleep Medicine, Davis Heart and Lung Institute, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.
JHLT open
|March 27, 2025
概括
用sotatercept治疗肺动脉高血压 (PAH) 可能会影响肺移植结果,因为副作用如血小板数量低和红细胞数量高. 本案例研究研究了在接受sotatercept治疗期间接受肺移植的第一个患者.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 肺动脉高血压 (PAH) 是肺移植的主要症候.
- 索塔特塞普特是一种新的PAH药物,已知有不良影响.
- 索塔切普特对移植结果的潜在影响尚未得到充分证实.
研究的目的:
- 报告第一个肺移植病例,该病例发生在接受PAH治疗的患者身上.
- 突出潜在的并发症和管理方面的考虑.
主要方法:
- 一个单一患者的病例报告.
- 对临床过程和管理策略的审查.
主要成果:
- 患者在接受sotatercept时接受了肺移植.
- 已经注意到了诸如血小板缺血和红细胞瘤等不良反应.
- 移植结果需要进一步监测.
结论:
- 肺移植可以在接受sotatercept的患者中进行.
- 在移植后,密切监测与sotatercept相关的不良事件至关重要.
- 需要进一步的研究来了解长期的结果.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
118
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
118
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
139
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
139